beta, beta-dimethylacrylshikonin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, J; Dai, X; Dai, Y; Gu, H; Li, H; Liu, C; Lv, L; Wang, O; Wang, X; Wang, Z; Wu, H; Wu, Z; Xia, E; Yan, C | 1 |
1 other study(ies) available for beta, beta-dimethylacrylshikonin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Immune Evasion; Mice; Network Pharmacology; Paclitaxel; Phosphorylation; Transcriptome; Triple Negative Breast Neoplasms | 2023 |